Developer docs
API playgroundTry for free, no card

Search company profiles

Opus Genetics

Full company profile

uuid00003px

Namestring
Opus Genetics
Legal namestring
Opus Genetics, Inc.
Websiteurl
opusgtx.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases (IRDs) and a small-molecule therapy for refractive disorders. Founded in September 2021 by the Retinal Degeneration Fund with $19 million in seed funding and headquartered in Durham, North Carolina, the company became a public entity in October 2024 through acquisition by Ocuphire Pharma and now trades on NASDAQ under ticker IRD. Its core technology is subretinal AAV gene delivery targeting the genetic causes of IRDs, with a seven-program pipeline: OPGx-LCA5 in Phase 3 (FDA designations including RMAT, Orphan Drug, Rare Pediatric Disease, and RDEP); OPGx-BEST1 in Phase 1/2; OPGx-MERTK in Phase 1/2 (launched in Abu Dhabi); and OPGx-RHO, OPGx-RDH12, OPGx-NMNAT1, and OPGx-CNGB1 in preclinical or IND-enabling stages. The OPGx-RHO program uses a differentiated silence-and-replace approach for autosomal dominant retinitis pigmentosa.

The company serves patients with ultra-rare and rare inherited retinal conditions, including approximately 170 U.S. patients with LCA5, ~8,400 with BEST1-related diseases, ~8,800 with RHO-adRP, ~2,500 with RDH12, ~2,600 with MERTK, ~1,200 with NMNAT1, and ~2,100 with CNGB1, totaling roughly 83,000 patients worldwide across all targeted indications. Its commercial-stage asset is phentolamine ophthalmic solution 0.75% (RYZUMVI), FDA-approved for drug-induced mydriasis with a pending sNDA for presbyopia (PDUFA date October 17, 2026), partnered exclusively with Viatris for U.S. commercialization.

Opus generates revenue primarily through licensing royalties and milestone payments on the Viatris-partnered phentolamine asset, with FY2025 consensus revenue of approximately $15.8M. The business model relies on a mix of equity capital raises (over $68M across 2025-2026 preferred and direct offerings), non-dilutive structured financing ($155M Oberland facility extending runway into 2029), and non-dilutive grants from the Foundation Fighting Blindness and Retinal Degeneration Fund to advance clinical development. The company has not yet commercialized a gene therapy product and remains pre-revenue on its core AAV pipeline.

Short descriptiontext

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases. Its seven-program pipeline targets ultra-rare genetic blindness conditions, with OPGx-LCA5 in Phase 3 and OPGx-BEST1 in Phase 1/2 development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRaleigh, United States
HQ citystring
Raleigh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy, ophthalmic biopharmaceuticals, inherited retinal diseases, AAV-based therapeutics, rare disease treatment
Industry5 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmic Gene Therapy Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Gene Therapy Product Sales
TypeOne Time License
Description

Revenue from FDA-approved gene therapy products for inherited retinal diseases, currently with one FDA-approved product and multiple programs in late-stage clinical development.

globenewswire.com
2Licensing Royalties - Viatris Partnership
TypeLicensing Royalties
Description

Royalty revenue from global licensing agreement with Viatris Inc. granting exclusive U.S. commercial rights to phentolamine ophthalmic solution 0.75% for presbyopia and visual disturbances.

prnewswire.com
3Strategic Financing
TypeManaged Services
Description

Non-dilutive funding arrangements including senior secured notes facility with Oberland Capital providing up to $155 million to support clinical development.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases (IRDs). Its pipeline includes seven gene therapy programs targeting genetic mutations including LCA5, BEST1, RHO, RDH12, MERTK, NMNAT1, and CNGB1, delivered via subretinal injection to restore or preserve vision. The company also has a partnered small-molecule ophthalmic product, phentolamine ophthalmic solution 0.75%, licensed to Viatris for U.S. commercialization for presbyopia and visual disturbances.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 30-fold improvements in cone sensitivity in pediatric LCA5 patients at 6 months with robust restoration of cone-mediated function following single subretinal injection
+3 more records
Product overview1 text field

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing a diversified portfolio of AAV-based gene therapies for inherited retinal diseases (IRDs), alongside a small-molecule therapy for ophthalmic disorders. The company's gene therapy pipeline includes seven programs: two in clinical development (OPGx-LCA5 in Phase 3 for LCA5, OPGx-BEST1 in Phase 1/2 for Best disease), three in IND-enabling stages (OPGx-RHO for autosomal dominant retinitis pigmentosa, OPGx-RDH12 and OPGx-MERTK for respective retinal dystrophies), and two in preclinical development (OPGx-NMNAT1 and OPGx-CNGB1). The company also has a partnered small-molecule product, phentolamine ophthalmic solution 0.75%, licensed to Viatris for U.S. commercialization. Opus executes a strategy centered on regulatory rigor, capital efficiency, and disciplined clinical development for rare inherited retinal conditions affecting over 2 million people worldwide.

Product and service8 records
1OPGx-LCA5
CategoryGene Therapy Program
Description

One-time subretinal AAV gene therapy delivering functional LCA5 gene to photoreceptors for Leber Congenital Amaurosis Type 5, an ultra-rare inherited retinal disease affecting approximately 170 people in the U.S. The therapy restores lebercilin protein essential for photoreceptor outer segment development.

2OPGx-BEST1
CategoryGene Therapy Program
Description

AAV vector-based gene therapy delivering functional BEST1 gene to restore bestrophin-1 protein production in retinal pigment epithelial cells for Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy, affecting approximately 8,400 people in the U.S.

3OPGx-RHO
CategoryGene Therapy Program
Description

Gene therapy targeting autosomal dominant retinitis pigmentosa caused by RHO mutations using a knockdown-and-replacement approach to preserve rod photoreceptors, affecting approximately 8,800 people in the U.S.

4OPGx-RDH12
CategoryGene Therapy Program
Description

Gene therapy targeting retinal dystrophy caused by RDH12 gene mutations, a severe early-onset IRD affecting approximately 2,500 people in the U.S.

5OPGx-MERTK
CategoryGene Therapy Program
Description

Gene therapy for retinal degeneration caused by MERTK gene mutations affecting approximately 2,600 people in the U.S., using modern AAV vector design with improved durability and efficacy targeting RPE cell phagocytosis of photoreceptor outer segments.

6OPGx-NMNAT1
CategoryPreclinical Gene Therapy Program
Description

Gene augmentation therapy designed to halt disease progression in pediatric patients with retinal degeneration caused by NMNAT1 gene mutations, affecting approximately 1,200 people in the U.S.; NMNAT1 is essential for regenerating NAD+.

7OPGx-CNGB1
CategoryPreclinical Gene Therapy Program
Description

AAV gene therapy for late-onset retinitis pigmentosa caused by CNGB1 gene mutations, affecting approximately 2,100 people in the U.S., being advanced in collaboration with NIH-funded academic consortium.

8Phentolamine Ophthalmic Solution 0.75%
CategorySmall Molecule Therapeutic
Description

Ophthalmic small-molecule solution for treatment of presbyopia and low-light visual disturbances. FDA-approved as RYZUMVI for drug-induced mydriasis with sNDA under FDA review for presbyopia. Licensed to Viatris for exclusive U.S. commercial rights.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-27
Description

Department of Health - Abu Dhabi announced launch and funding of UAE's first clinical trial for gene therapy targeting MERTK-related retinitis pigmentosa through Abu Dhabi's Healthcare Research and Innovation Fund, positioning Abu Dhabi as a hub for precision medicine and biotech innovation.

Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-01-27
Description

Clinical trial evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa conducted at Cleveland Clinic Abu Dhabi, representing first clinical opportunity for patients with this hereditary retinal disease.

Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-01-27
Description

M42's IROS (International Research Office Services) division provides clinical operations oversight for the OPGx-MERTK gene therapy trial in Abu Dhabi.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Global licensing agreement granting Viatris exclusive U.S. commercial rights to phentolamine ophthalmic solution 0.75% for presbyopia treatment. Viatris presented Phase 3 data at ASCRS 2026 and holds PDUFA goal date of October 17, 2026 for sNDA approval.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

World-class science from gene therapy pioneers including Dr. Jean Bennett's lab at Penn, which co-founded Spark Therapeutics (acquired by Roche) and other gene therapy companies.

6Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered with gene therapy pioneers at Harvard Medical School contributing to Opus' IRD program development based on world-class science.

opusgtx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered with gene therapy pioneers at University of Florida contributing to Opus' IRD program development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with NIH-funded academic consortium to advance OPGx-CNGB1 into and through a Phase 1 clinical trial for late-onset retinitis pigmentosa caused by CNGB1 gene mutations.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partnership with Foundation for the NIH's Bespoke Gene Therapy Consortium for OPGx-CNGB1 program to advance gene therapy for CNGB1-related retinitis pigmentosa.

Strategic tierMinorTypeOthers
Description

Patient advocacy group partner supporting patients and families affected by inherited retinal diseases.

Strategic tierMinorTypeOthers
Description

Patient advocacy group partner founded by Silvia Cerolini to fund and develop gene therapies for rare genetic disorders affecting vision, raising over $6 million across more than 20 countries.

Strategic tierMinorTypeOthers
Description

Patient advocacy group focused on supporting RDH12 patients and families affected by RDH12-associated retinal dystrophy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65 mutation). Most direct comparable: same modality (subretinal AAV), same indication class (IRDs), and same patient/physician ecosystem.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases including wet AMD and IRDs. Competes in the same AAV-ocular delivery space and targets overlapping ophthalmology centers and patient identification infrastructure.

TypeDirect peer
Description

Clinical-stage gene therapy company with multiple IRD programs (including AAV-RPGR for X-linked retinitis pigmentosa) and integrated AAV manufacturing. Direct competitor for AAV ocular delivery and IRD patient populations.

TypeDirect peer
Description

Clinical and commercial-stage AAV gene therapy company with ocular programs (ABBV-RGX-314 for wet AMD via subretinal/suprachoroidal delivery) and a proprietary AAV platform. Competes on AAV technology, manufacturing scale, and ophthalmic indication strategy.

TypeEmerging player
Description

Clinical-stage gene therapy company with a directed-evolution AAV platform and ophthalmology programs including 4D-150 for wet AMD. Emerging peer with next-generation AAV capsids that may offer delivery advantages over Opus's subretinal approach.

TypeEmerging player
Description

Preclinical/early-clinical gene therapy company developing optogenetic therapies for retinal degeneration. Comparable as an IRD-focused AAV gene therapy developer with similar patient-identification and ophthalmic-center commercialization model.

TypeEmerging player
Description

Clinical-stage gene therapy company developing AAV-based therapies for ocular and CNS diseases, including IRDs. Comparable platform technology and target patient population, with focus on ultra-rare ophthalmic indications.

8SparingVision
TypeEmerging player
Description

Clinical-stage gene therapy company developing therapies for IRDs including retinitis pigmentosa, with both gene-augmentation and mutation-independent approaches. Directly comparable as an IRD-focused AAV gene therapy developer targeting similar patient populations.

TypeEmerging player
Description

Clinical-stage gene therapy company developing AAV-based therapies for IRDs, including Lumevoq for Leber Hereditary Optic Neuropathy. Comparable in modality, target indications, and co-founded by scientific advisors in Opus's network.

TypeOthers
Description

Opus's U.S. commercial partner for phentolamine ophthalmic solution 0.75% and a broader ophthalmic and specialty pharmaceutical company. Relevant as Opus's primary commercialization vehicle for its non-gene-therapy assets and as a strategic counterparty.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Opus Genetics

Ophthalmic Gene Therapy Pharmaceuticalsopusgtx.com

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases. Its seven-program pipeline targets ultra-rare genetic blindness conditions, with OPGx-LCA5 in Phase 3 and OPGx-BEST1 in Phase 1/2 development.

What Opus Genetics does

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases (IRDs) and a small-molecule therapy for refractive disorders. Founded in September 2021 by the Retinal Degeneration Fund with $19 million in seed funding and headquartered in Durham, North Carolina, the company became a public entity in October 2024 through acquisition by Ocuphire Pharma and now trades on NASDAQ under ticker IRD. Its core technology is subretinal AAV gene delivery targeting the genetic causes of IRDs, with a seven-program pipeline: OPGx-LCA5 in Phase 3 (FDA designations including RMAT, Orphan Drug, Rare Pediatric Disease, and RDEP); OPGx-BEST1 in Phase 1/2; OPGx-MERTK in Phase 1/2 (launched in Abu Dhabi); and OPGx-RHO, OPGx-RDH12, OPGx-NMNAT1, and OPGx-CNGB1 in preclinical or IND-enabling stages. The OPGx-RHO program uses a differentiated silence-and-replace approach for autosomal dominant retinitis pigmentosa.

The company serves patients with ultra-rare and rare inherited retinal conditions, including approximately 170 U.S. patients with LCA5, ~8,400 with BEST1-related diseases, ~8,800 with RHO-adRP, ~2,500 with RDH12, ~2,600 with MERTK, ~1,200 with NMNAT1, and ~2,100 with CNGB1, totaling roughly 83,000 patients worldwide across all targeted indications. Its commercial-stage asset is phentolamine ophthalmic solution 0.75% (RYZUMVI), FDA-approved for drug-induced mydriasis with a pending sNDA for presbyopia (PDUFA date October 17, 2026), partnered exclusively with Viatris for U.S. commercialization.

Opus generates revenue primarily through licensing royalties and milestone payments on the Viatris-partnered phentolamine asset, with FY2025 consensus revenue of approximately $15.8M. The business model relies on a mix of equity capital raises (over $68M across 2025-2026 preferred and direct offerings), non-dilutive structured financing ($155M Oberland facility extending runway into 2029), and non-dilutive grants from the Foundation Fighting Blindness and Retinal Degeneration Fund to advance clinical development. The company has not yet commercialized a gene therapy product and remains pre-revenue on its core AAV pipeline.

Opus Genetics firmographics

Firmographics
Name
Opus Genetics
Legal name
Opus Genetics, Inc.
Website
https://opusgtx.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases. Its seven-program pipeline targets ultra-rare genetic blindness conditions, with OPGx-LCA5 in Phase 3 and OPGx-BEST1 in Phase 1/2 development.
Ownership category
akta.pro rank

Opus Genetics industry classification

Industry
Product category
Ophthalmic Gene Therapy Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Gene therapy
  • Ophthalmic biopharmaceuticals
  • Inherited retinal diseases
  • AAV-based therapeutics
  • Rare disease treatment

Where Opus Genetics is headquartered

Location

Headquarters

HQ city
Raleigh
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Opus Genetics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Gene Therapy Product Sales: Revenue from FDA-approved gene therapy products for inherited retinal diseases, currently with one FDA-approved product and multiple programs in late-stage clinical development.
  2. Licensing Royalties - Viatris Partnership: Royalty revenue from global licensing agreement with Viatris Inc. granting exclusive U.S. commercial rights to phentolamine ophthalmic solution 0.75% for presbyopia and visual disturbances.
  3. Strategic Financing: Non-dilutive funding arrangements including senior secured notes facility with Oberland Capital providing up to $155 million to support clinical development.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Opus Genetics product offering

Product offering

Core offering

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases (IRDs). Its pipeline includes seven gene therapy programs targeting genetic mutations including LCA5, BEST1, RHO, RDH12, MERTK, NMNAT1, and CNGB1, delivered via subretinal injection to restore or preserve vision. The company also has a partnered small-molecule ophthalmic product, phentolamine ophthalmic solution 0.75%, licensed to Viatris for U.S. commercialization for presbyopia and visual disturbances.

Product overview

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing a diversified portfolio of AAV-based gene therapies for inherited retinal diseases (IRDs), alongside a small-molecule therapy for ophthalmic disorders. The company's gene therapy pipeline includes seven programs: two in clinical development (OPGx-LCA5 in Phase 3 for LCA5, OPGx-BEST1 in Phase 1/2 for Best disease), three in IND-enabling stages (OPGx-RHO for autosomal dominant retinitis pigmentosa, OPGx-RDH12 and OPGx-MERTK for respective retinal dystrophies), and two in preclinical development (OPGx-NMNAT1 and OPGx-CNGB1). The company also has a partnered small-molecule product, phentolamine ophthalmic solution 0.75%, licensed to Viatris for U.S. commercialization. Opus executes a strategy centered on regulatory rigor, capital efficiency, and disciplined clinical development for rare inherited retinal conditions affecting over 2 million people worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • OPGx-LCA5 One-time subretinal AAV gene therapy delivering functional LCA5 gene to photoreceptors for Leber Congenital Amaurosis Type 5, an ultra-rare inherited retinal disease affecting approximately 170 people in the U.S. The therapy restores lebercilin protein essential for photoreceptor outer segment development.
  • OPGx-BEST1 AAV vector-based gene therapy delivering functional BEST1 gene to restore bestrophin-1 protein production in retinal pigment epithelial cells for Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy, affecting approximately 8,400 people in the U.S.
  • OPGx-RHO Gene therapy targeting autosomal dominant retinitis pigmentosa caused by RHO mutations using a knockdown-and-replacement approach to preserve rod photoreceptors, affecting approximately 8,800 people in the U.S.
  • OPGx-RDH12 Gene therapy targeting retinal dystrophy caused by RDH12 gene mutations, a severe early-onset IRD affecting approximately 2,500 people in the U.S.
  • OPGx-MERTK Gene therapy for retinal degeneration caused by MERTK gene mutations affecting approximately 2,600 people in the U.S., using modern AAV vector design with improved durability and efficacy targeting RPE cell phagocytosis of photoreceptor outer segments.
  • OPGx-NMNAT1 Gene augmentation therapy designed to halt disease progression in pediatric patients with retinal degeneration caused by NMNAT1 gene mutations, affecting approximately 1,200 people in the U.S.; NMNAT1 is essential for regenerating NAD+.
  • OPGx-CNGB1 AAV gene therapy for late-onset retinitis pigmentosa caused by CNGB1 gene mutations, affecting approximately 2,100 people in the U.S., being advanced in collaboration with NIH-funded academic consortium.
  • Phentolamine Ophthalmic Solution 0.75% Ophthalmic small-molecule solution for treatment of presbyopia and low-light visual disturbances. FDA-approved as RYZUMVI for drug-induced mydriasis with sNDA under FDA review for presbyopia. Licensed to Viatris for exclusive U.S. commercial rights.

Quantifiable outcome

  • Over 30-fold improvements in cone sensitivity in pediatric LCA5 patients at 6 months with robust restoration of cone-mediated function following single subretinal injection
  • +3 more outcomes

Companies that use Opus Genetics

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Opus Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Opus Genetics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered major, core and minor.

  • Department of Health - Abu DhabimajorStrategic or Co-development Partner · 27 January 2026Department of Health - Abu Dhabi announced launch and funding of UAE's first clinical trial for gene therapy targeting MERTK-related retinitis pigmentosa through Abu Dhabi's Healthcare Research and Innovation Fund, positioning Abu Dhabi as a hub for precision medicine and biotech innovation.
  • Cleveland Clinic Abu DhabimajorImplementation/ SI/ Consulting Partner · 27 January 2026Clinical trial evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa conducted at Cleveland Clinic Abu Dhabi, representing first clinical opportunity for patients with this hereditary retinal disease.
  • M42's IROS DivisionmajorImplementation/ SI/ Consulting Partner · 27 January 2026M42's IROS (International Research Office Services) division provides clinical operations oversight for the OPGx-MERTK gene therapy trial in Abu Dhabi.
  • Viatris Inc.coreChannel Partner/ Reseller/ DistributorGlobal licensing agreement granting Viatris exclusive U.S. commercial rights to phentolamine ophthalmic solution 0.75% for presbyopia treatment. Viatris presented Phase 3 data at ASCRS 2026 and holds PDUFA goal date of October 17, 2026 for sNDA approval.
  • University of PennsylvaniacoreStrategic or Co-development PartnerWorld-class science from gene therapy pioneers including Dr. Jean Bennett's lab at Penn, which co-founded Spark Therapeutics (acquired by Roche) and other gene therapy companies.
  • Harvard Medical SchoolcoreStrategic or Co-development PartnerPartnered with gene therapy pioneers at Harvard Medical School contributing to Opus' IRD program development based on world-class science.
  • University of FloridacoreStrategic or Co-development PartnerPartnered with gene therapy pioneers at University of Florida contributing to Opus' IRD program development.
  • NIH-funded Academic ConsortiummajorStrategic or Co-development PartnerCollaboration with NIH-funded academic consortium to advance OPGx-CNGB1 into and through a Phase 1 clinical trial for late-onset retinitis pigmentosa caused by CNGB1 gene mutations.
  • Foundation for the NIH's Bespoke Gene Therapy ConsortiummajorStrategic or Co-development PartnerPartnership with Foundation for the NIH's Bespoke Gene Therapy Consortium for OPGx-CNGB1 program to advance gene therapy for CNGB1-related retinitis pigmentosa.
  • Hope in FocusminorOthersPatient advocacy group partner supporting patients and families affected by inherited retinal diseases.
  • Eyes on the FutureminorOthersPatient advocacy group partner founded by Silvia Cerolini to fund and develop gene therapies for rare genetic disorders affecting vision, raising over $6 million across more than 20 countries.
  • RDH12 Fund for SightminorOthersPatient advocacy group focused on supporting RDH12 patients and families affected by RDH12-associated retinal dystrophy.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Opus Genetics competitors and assessment

Company assessment

Direct peers

  • Spark Therapeutics (Roche): Developer of Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65 mutation). Most direct comparable: same modality (subretinal AAV), same indication class (IRDs), and same patient/physician ecosystem.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases including wet AMD and IRDs. Competes in the same AAV-ocular delivery space and targets overlapping ophthalmology centers and patient identification infrastructure.
  • MeiraGTx: Clinical-stage gene therapy company with multiple IRD programs (including AAV-RPGR for X-linked retinitis pigmentosa) and integrated AAV manufacturing. Direct competitor for AAV ocular delivery and IRD patient populations.
  • REGENXBIO: Clinical and commercial-stage AAV gene therapy company with ocular programs (ABBV-RGX-314 for wet AMD via subretinal/suprachoroidal delivery) and a proprietary AAV platform. Competes on AAV technology, manufacturing scale, and ophthalmic indication strategy.

Emerging players

  • 4D Molecular Therapeutics: Clinical-stage gene therapy company with a directed-evolution AAV platform and ophthalmology programs including 4D-150 for wet AMD. Emerging peer with next-generation AAV capsids that may offer delivery advantages over Opus's subretinal approach.
  • Ray Therapeutics: Preclinical/early-clinical gene therapy company developing optogenetic therapies for retinal degeneration. Comparable as an IRD-focused AAV gene therapy developer with similar patient-identification and ophthalmic-center commercialization model.
  • Coave Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for ocular and CNS diseases, including IRDs. Comparable platform technology and target patient population, with focus on ultra-rare ophthalmic indications.
  • SparingVision: Clinical-stage gene therapy company developing therapies for IRDs including retinitis pigmentosa, with both gene-augmentation and mutation-independent approaches. Directly comparable as an IRD-focused AAV gene therapy developer targeting similar patient populations.
  • GenSight Biologics: Clinical-stage gene therapy company developing AAV-based therapies for IRDs, including Lumevoq for Leber Hereditary Optic Neuropathy. Comparable in modality, target indications, and co-founded by scientific advisors in Opus's network.

Others

  • Viatris (Ophthalmology): Opus's U.S. commercial partner for phentolamine ophthalmic solution 0.75% and a broader ophthalmic and specialty pharmaceutical company. Relevant as Opus's primary commercialization vehicle for its non-gene-therapy assets and as a strategic counterparty.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Opus Genetics social profiles

Digital presence

Opus Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Opus Genetics leadership team

Management profile

Number of profiles

Profiles10 records

Opus Genetics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Opus Genetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opus Genetics

What does Opus Genetics do?

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies for inherited retinal diseases (IRDs). Its pipeline includes seven gene therapy programs targeting genetic mutations including LCA5, BEST1, RHO, RDH12, MERTK, NMNAT1, and CNGB1, delivered via subretinal injection to restore or preserve vision. The company also has a partnered small-molecule ophthalmic product, phentolamine ophthalmic solution 0.75%, licensed to Viatris for U.S. commercialization for presbyopia and visual disturbances.

Is Opus Genetics a public or private company?

Opus Genetics is a public company. It is classified as public and is currently operating.

When was Opus Genetics founded?

Opus Genetics was founded in 2021. It employs 11 to 50 people.

Where is Opus Genetics based?

Opus Genetics is headquartered in Raleigh, United States, in the North America region.

How does Opus Genetics make money?

Three revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are licensing Royalties - Viatris Partnership and strategic Financing.

Who are Opus Genetics's main competitors?

Direct peers on record are Spark Therapeutics (Roche), Adverum Biotechnologies, MeiraGTx and REGENXBIO. Emerging players are 4D Molecular Therapeutics, Ray Therapeutics, Coave Therapeutics, SparingVision and GenSight Biologics. Viatris (Ophthalmology) is listed as an others.

Does Opus Genetics have an API?

No public API is recorded for Opus Genetics.

What industry is Opus Genetics in?

Opus Genetics's product category is Ophthalmic Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAG, Ophthalmology Gene Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsOpus Genetics (NASDAQ:IRD) Stock Rating Reaffirmed as “Buy” by Chardan CapitalChardan Capital reaffirmed a buy rating on Opus Genetics with a $16 price target, implying 249.34% upside. The stock opened at $4.58, and the company reported Q2 EPS of -$0.14, beating the -$0.16 consensus estimate, though revenue of $0.76 million missed the $2.63 million forecast.TradingViewChardan Capital maintains Buy rating on Opus Genetics, $16 price targetChardan Capital maintained a Buy rating on Opus Genetics with a $16 price target, implying 254.8% upside from the Oct 1 close of $4.51. The company has a robust pipeline of AAV-based gene therapies for inherited retinal diseases, with Phase 3 dosing for OPGx-LCA5 set to begin soon.American Banking and Market NewsOpus Genetics, Inc. (NASDAQ:IRD) Stock Has Consensus Price Target of $11.92Opus Genetics shares have an average analyst price target of $11.92 with a Moderate Buy consensus. The company reported a Q2 loss of $0.14 per share, missing estimates, and revenue of $0.76 million versus $2.63 million expected. Insiders sold 57,331 shares over three months.BioWorldOpus BEST1 and done? Gene therapy scores in rare eye diseasesOpus Genetics is advancing its gene therapy OPGx-BEST1 for Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy, based on upbeat data from an ongoing phase I/II trial. The therapy targets mutations in the BEST1 gene, with no approved treatments for either condition.Investing.comWedbush raises Opus Genetics stock price target on FDA alignment By Investing.comWedbush raised its price target on Opus Genetics to $13 from $10, maintaining an Outperform rating. The firm increased the estimated probability of success for the OPGx-BEST1 program to 50% after FDA alignment on pivotal endpoints. The company expects 3-month top-line data from Cohort 2 in Q2 2027.Quiver QuantitativeOpus Genetics Reports Positive Interim Phase 1/2 Results for OPGx-BEST1 in BEST1-Related Retinal Diseases | IRD Stock NewsOpus Genetics reported positive interim results from Cohort 1 of its Phase 1/2 trial for OPGx-BEST1, with all five participants showing clinically meaningful visual improvements and structural gains in four. The FDA aligned on a potential pivotal endpoint, and Cohort 2 dosing is expected to complete in Q4 2026 with topline data in Q2 2027.Investing.comOpus Genetics stock maintains buy rating ahead of trial data By Investing.comTD Cowen reiterated a Buy rating on Opus Genetics ahead of upcoming Phase 1b/2a clinical trial results for its gene therapy OPGx-BEST1, scheduled for release in September 2026. The analyst firm cited preclinical data and early sentinel patient results as supportive factors, setting a high price target of $16. Other firms including Citizens and Cantor Fitzgerald have also maintained positive ratings on the company's stock.Clinical LeaderHow FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development StrategyOpus Genetics has reached an agreement with the FDA on a streamlined registrational Phase 3 study design for its investigational gene therapy OPGx-LCA5, targeting Leber congenital amaurosis type 5. The company plans to begin dosing patients later this year using a self-controlled trial design and validated commercial manufacturing processes. This alignment reflects a collaborative regulatory approach for ultra-rare diseases where traditional randomized controlled trials are not feasible.Eyes On EyecareOpus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapyOpus Genetics announced the completion of patient enrollment for its registrational phase 3 clinical trial of OPGx-LCA5, a gene therapy targeting LCA5-associated inherited retinal disease. The company remains on track to initiate dosing in the fourth quarter of 2026 and report topline data by the end of 2027. This milestone follows previous FDA designations and early clinical data showing improved visual function and safety in pediatric and adult patients.